STOCK TITAN

[Form 4] BioAtla, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Richard A. Waldron, Chief Financial Officer of BioAtla, Inc. (BCAB), reported a transaction dated 08/31/2025 in which 2,371 shares of common stock were disposed of under code F(1) at a price of $0.4555 per share. The filing states these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations related to the vesting and net settlement of previously reported restricted stock units. Following the withholding, the reporting person beneficially owns 338,521 shares (direct ownership). The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/02/2025.

Richard A. Waldron, Chief Financial Officer di BioAtla, Inc. (BCAB), ha comunicato una transazione datata 31/08/2025 con la quale sono state cedute 2.371 azioni ordinarie in base al codice F(1) al prezzo di $0,4555 per azione. Il deposito indica che queste azioni sono state trattenute dall'emittente per adempiere agli obblighi di ritenuta e versamento delle imposte sul reddito connessi al vesting e al regolamento netto di unità azionarie ristrette precedentemente segnalate. A seguito della ritenuta, la persona che ha effettuato la segnalazione detiene beneficiariamente 338.521 azioni (proprietà diretta). Il Modulo 4 è stato presentato da un unico soggetto segnalante ed è stato firmato da un procuratore il 02/09/2025.

Richard A. Waldron, Director Financiero de BioAtla, Inc. (BCAB), informó una operación con fecha 31/08/2025 en la que se dispusieron 2.371 acciones ordinarias bajo el código F(1) a un precio de $0,4555 por acción. El informe indica que dichas acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención y remisión de impuestos sobre la renta relacionadas con el vencimiento y la liquidación neta de unidades de acciones restringidas previamente reportadas. Tras la retención, la persona que informa posee beneficiariamente 338.521 acciones (propiedad directa). El Formulario 4 fue presentado por una sola persona informante y firmado por un apoderado el 02/09/2025.

Richard A. Waldron, BioAtla, Inc. (BCAB) 최고재무책임자는 2025-08-31자 거래를 보고했으며, 해당 거래에서 2,371주의 보통주가 코드 F(1)로 주당 $0.4555에 처분되었습니다. 신고서에는 이 주식들이 이전에 보고된 제한주(RSU)의 베스팅 및 순결제와 관련한 소득세 원천징수 및 납부 의무를 충당하기 위해 발행사가 원천징수한 것이라고 명시되어 있습니다. 원천징수 후 신고인은 혜택적 보유자로서 338,521주를 보유하고 있습니다(직접 보유). Form 4는 한 명의 신고인이 제출했으며 2025-09-02에 대리인이 서명했습니다.

Richard A. Waldron, directeur financier de BioAtla, Inc. (BCAB), a déclaré une opération datée du 31/08/2025 au cours de laquelle 2 371 actions ordinaires ont été cédées selon le code F(1) au prix de 0,4555 $ par action. Le dépôt indique que ces actions ont été retenues par l'émetteur pour satisfaire les obligations de retenue et de versement de l'impôt sur le revenu liées à la levée des restrictions et au règlement net d'unités d'actions restreintes précédemment signalées. Après cette retenue, la personne déclarante détient à titre bénéficiaire 338 521 actions (propriété directe). Le formulaire 4 a été déposé par une seule personne déclarante et signé par un mandataire le 02/09/2025.

Richard A. Waldron, Chief Financial Officer von BioAtla, Inc. (BCAB), meldete eine Transaktion vom 31.08.2025, bei der 2.371 Stammaktien unter dem Code F(1) zu einem Preis von $0,4555 pro Aktie veräußert wurden. Die Einreichung besagt, dass diese Aktien vom Emittenten einbehalten wurden, um Verpflichtungen zur Lohnsteuerabführung und -überweisung im Zusammenhang mit dem Vesting und der Nettoregelung zuvor gemeldeter Restricted Stock Units zu erfüllen. Nach dem Einbehalt besitzt die meldende Person wirtschaftlich 338.521 Aktien (direkter Besitz). Das Formular 4 wurde von einer meldenden Person eingereicht und am 02.09.2025 von einem Bevollmächtigten unterschrieben.

Positive
  • Transaction clearly disclosed as a tax withholding for vested restricted stock units, including code F(1), price, and date
  • Post-transaction beneficial ownership specified: 338,521 shares (direct)
  • Form filed and signed (attorney-in-fact signature dated 09/02/2025), meeting reporting protocol
Negative
  • None.

Insights

TL;DR: Routine insider withholding for vested RSUs; small, non-sale disposition documented.

This Form 4 documents a tax-withholding disposition (code F(1)) of 2,371 shares related to the vesting and net settlement of previously reported restricted stock units. The report shows the reporting person retains beneficial ownership of 338,521 shares after the withholding. The transaction is recorded as a disposition but is explicitly described as a withholding to satisfy tax obligations rather than an open-market sale, which is a common administrative step following equity vesting.

TL;DR: Administrative equity withholding recorded; disclosure meets Section 16 reporting requirements.

The filing clearly identifies the nature of the transaction as issuer-withheld shares to cover tax withholding on vested RSUs, includes the transaction code F(1), the per-share price of $0.4555, the date of transaction, and the post-transaction beneficial ownership. The Form is signed by an attorney-in-fact and filed as a single reporting person submission, providing the required transparency for insider compensation-related equity events.

Richard A. Waldron, Chief Financial Officer di BioAtla, Inc. (BCAB), ha comunicato una transazione datata 31/08/2025 con la quale sono state cedute 2.371 azioni ordinarie in base al codice F(1) al prezzo di $0,4555 per azione. Il deposito indica che queste azioni sono state trattenute dall'emittente per adempiere agli obblighi di ritenuta e versamento delle imposte sul reddito connessi al vesting e al regolamento netto di unità azionarie ristrette precedentemente segnalate. A seguito della ritenuta, la persona che ha effettuato la segnalazione detiene beneficiariamente 338.521 azioni (proprietà diretta). Il Modulo 4 è stato presentato da un unico soggetto segnalante ed è stato firmato da un procuratore il 02/09/2025.

Richard A. Waldron, Director Financiero de BioAtla, Inc. (BCAB), informó una operación con fecha 31/08/2025 en la que se dispusieron 2.371 acciones ordinarias bajo el código F(1) a un precio de $0,4555 por acción. El informe indica que dichas acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención y remisión de impuestos sobre la renta relacionadas con el vencimiento y la liquidación neta de unidades de acciones restringidas previamente reportadas. Tras la retención, la persona que informa posee beneficiariamente 338.521 acciones (propiedad directa). El Formulario 4 fue presentado por una sola persona informante y firmado por un apoderado el 02/09/2025.

Richard A. Waldron, BioAtla, Inc. (BCAB) 최고재무책임자는 2025-08-31자 거래를 보고했으며, 해당 거래에서 2,371주의 보통주가 코드 F(1)로 주당 $0.4555에 처분되었습니다. 신고서에는 이 주식들이 이전에 보고된 제한주(RSU)의 베스팅 및 순결제와 관련한 소득세 원천징수 및 납부 의무를 충당하기 위해 발행사가 원천징수한 것이라고 명시되어 있습니다. 원천징수 후 신고인은 혜택적 보유자로서 338,521주를 보유하고 있습니다(직접 보유). Form 4는 한 명의 신고인이 제출했으며 2025-09-02에 대리인이 서명했습니다.

Richard A. Waldron, directeur financier de BioAtla, Inc. (BCAB), a déclaré une opération datée du 31/08/2025 au cours de laquelle 2 371 actions ordinaires ont été cédées selon le code F(1) au prix de 0,4555 $ par action. Le dépôt indique que ces actions ont été retenues par l'émetteur pour satisfaire les obligations de retenue et de versement de l'impôt sur le revenu liées à la levée des restrictions et au règlement net d'unités d'actions restreintes précédemment signalées. Après cette retenue, la personne déclarante détient à titre bénéficiaire 338 521 actions (propriété directe). Le formulaire 4 a été déposé par une seule personne déclarante et signé par un mandataire le 02/09/2025.

Richard A. Waldron, Chief Financial Officer von BioAtla, Inc. (BCAB), meldete eine Transaktion vom 31.08.2025, bei der 2.371 Stammaktien unter dem Code F(1) zu einem Preis von $0,4555 pro Aktie veräußert wurden. Die Einreichung besagt, dass diese Aktien vom Emittenten einbehalten wurden, um Verpflichtungen zur Lohnsteuerabführung und -überweisung im Zusammenhang mit dem Vesting und der Nettoregelung zuvor gemeldeter Restricted Stock Units zu erfüllen. Nach dem Einbehalt besitzt die meldende Person wirtschaftlich 338.521 Aktien (direkter Besitz). Das Formular 4 wurde von einer meldenden Person eingereicht und am 02.09.2025 von einem Bevollmächtigten unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WALDRON RICHARD A

(Last) (First) (Middle)
C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/31/2025 F(1) 2,371 D $0.4555 338,521 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.
/s/ Christian Vasquez, as Attorney-in-Fact for Richard A. Waldron 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioAtla (BCAB) insider Richard A. Waldron report on Form 4?

The filing reports a withholding disposition of 2,371 common shares on 08/31/2025 related to vested RSUs, at a price of $0.4555 per share.

Why were the 2,371 shares disposed of according to the Form 4?

The Form 4 states the shares were withheld by the issuer to satisfy income tax and withholding and remittance obligations in connection with vesting and net settlement of previously reported restricted stock units.

How many shares does Richard A. Waldron beneficially own after the transaction?

Following the withholding, the reporting person beneficially owns 338,521 shares (direct ownership).

What transaction code was used on the Form 4 and what does it indicate?

Transaction code F(1) is used; the filing explains this represents shares withheld to satisfy tax obligations related to RSU vesting (not an open-market sale).

Who signed the Form 4 for Richard A. Waldron and when?

The Form 4 was signed by Christian Vasquez, as Attorney-in-Fact, on 09/02/2025.
Bioatla, Inc.

NASDAQ:BCAB

BCAB Rankings

BCAB Latest News

BCAB Latest SEC Filings

BCAB Stock Data

26.75M
52.22M
10.6%
29.76%
6.71%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO